|1.||Ellis, Ruth D: 8 articles (12/2014 - 01/2008)|
|2.||Miura, Kazutoyo: 7 articles (12/2014 - 01/2008)|
|3.||Fay, Michael P: 6 articles (01/2011 - 01/2008)|
|4.||Miller, Louis H: 6 articles (01/2010 - 01/2008)|
|5.||Mullen, Gregory E D: 6 articles (01/2010 - 03/2006)|
|6.||Long, Carole A: 5 articles (12/2014 - 03/2006)|
|7.||Martin, Laura B: 5 articles (01/2010 - 05/2009)|
|8.||Saul, Allan: 5 articles (10/2009 - 03/2006)|
|9.||Zhu, Daming: 4 articles (12/2014 - 01/2008)|
|10.||Dicko, Alassane: 4 articles (01/2011 - 12/2008)|
01/01/2001 - "These recommendations concern the use of aluminum hydroxide adsorbed cell-free anthrax vaccine (Anthrax Vaccine Adsorbed [AVA], BioPort Corporation, Lansing, MI) in the United States for protection against disease caused by Bacillus anthracis. "
12/15/2000 - "These recommendations concern the use of aluminum hydroxide adsorbed cell-free anthrax vaccine (Anthrax Vaccine Adsorbed [AVA], BioPort Corporation, Lansing, MI) in the United States for protection against disease caused by Bacillus anthracis. "
05/31/2002 - "Anthrax vaccine, adsorbed (AVA) is a vaccine containing aluminum hydroxide that is administered as six subcutaneous (s.q.) doses over 18 months. "
08/14/2006 - "Hundred healthy volunteers were randomized in a 4:1 ratio to receive intramuscular doses of rPA102 in the following formulations: 5, 25, 50, or 75 microg of rPA102 in 82.5 microg aluminum hydroxide adjuvant at 0, 4, and 8 weeks; or the US licensed Anthrax Vaccine Adsorbed (AVA) at weeks 0 and 4. Local reactogenicity (mostly pain) was more common with AVA than with rPA102 following the first (94.7% versus 44.4%; p < 0.001) and the second (84.2% versus 35.4%; p < 0.001) vaccinations. "
04/02/2012 - "Advancements toward an improved vaccine against Bacillus anthracis, the causative agent of anthrax, have focused on formulations composed of the protective antigen (PA) adsorbed to aluminum hydroxide. "
01/01/2013 - "Previous clinical trials indicated the protective efficacy of BK-SE36 malaria vaccine that is constituted of SE36 recombinant protein and aluminum hydroxide gel. "
01/01/2011 - "A Phase 1-2b study of the blood stage malaria vaccine AMA1-C1/Alhydrogel was conducted in 336 children in Donéguébougou and Bancoumana, Mali. "
05/18/2009 - "A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali."
04/12/2011 - "GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. "
02/01/2002 - "Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model."
|3.||Human Influenza (Influenza)
12/01/2011 - "Effect of aluminum hydroxide adjuvant on the immunogenicity of the 2009 pandemic influenza A/H1N1 vaccine: multi-level modeling of data with repeated measures."
11/05/2009 - "Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults."
08/13/2009 - "Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults."
11/01/2008 - "Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial."
10/01/1996 - "A challenge study was conducted to evaluate the safety and efficacy of an inactivated influenza H3N2 virus vaccine combined with Quil A/Alhydrogel mixture under controlled conditions in piglets. "
02/10/2011 - "Aluminum hydroxide-ginseng extract and inactivated tachyzoites reduced the number of parasites circulating in the blood during acute phase but failed to limit the establishment of chronic infection. "
05/01/2010 - "Pretreatment with aluminum hydroxide before pathogen challenge reduced the development of Ralstonia solanacearum infection and decreased the extent of leaf injury. "
12/01/2009 - "We sought to define protective mechanisms of immunity to Staphylococcus aureus and Candida albicans bloodstream infections in mice immunized with the recombinant N-terminus of Als3p (rAls3p-N) vaccine plus aluminum hydroxide (Al(OH(3)) adjuvant, or adjuvant controls. "
01/07/2009 - "These observations demonstrate that baculovirus-produced rWNV-E can be formulated with aluminum hydroxide to produce a stable and safe vaccine which induces humoral immunity that can protect against WNV infection."
06/10/2005 - "This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections."
08/01/2005 - "Effectiveness of aluminum hydroxide timing administration in relation to meals in controlling hyperphosphatemia in dialysis patients."
05/01/1986 - "An infant with uremia due to congenital renal hypoplasia was treated with oral aluminum hydroxide for 9 months in an attempt to reduce hyperphosphatemia. "
05/03/1972 - "[Aluminum hydroxide treatment of hyperphosphatemia in uremia]."
08/01/2006 - "Treatment of hyperphosphatemia reduces dietary phosphate intake and includes phosphate binders such as aluminum hydroxide and aluminum carbonate. "
08/01/1995 - "Aluminum hydroxide and calcium compounds are used currently as phosphate-binding agents to treat hyperphosphatemia, but these compounds can cause undesirable side effects. "
|2.||aluminum sulfate (alum)
|3.||Magnesium Hydroxide (Brucite)
|4.||Aluminum Hydroxide (Algeldrate)
|5.||Calcium Carbonate (Limestone)
|9.||Merozoite Surface Protein 1 (MSA1)
|1.||Renal Dialysis (Hemodialysis)
|3.||Low-Level Laser Therapy (LLLT)
|5.||Drug Therapy (Chemotherapy)